Compare General Dynamics Corporation (GD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Mesoblast Limited — how do they compare? General Dynamics Corporation trades at $391.11 (market cap $106.03B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: General Dynamics Corporation is far larger — about 48× Mesoblast Limited's market cap, and General Dynamics Corporation pays a 1.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GD | MESO | |
|---|---|---|
Market Cap | $106.03B | $2.21B |
Sector | Industrials | Technology |
52-Week High | $395.97 | $20.96 |
52-Week Low | $312.53 | $12.88 |
Enterprise Value | $111.17B | $2.21B |
Dividend Yield | 1.62% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
